Shanghai Shanjin Asset Management Co., Ltd. (Shanjin Capital) was founded in 2016 . The current management scale exceeds 1 billion RMB.
As a private equity fund manager, the goal set by Shanjin Capital is to focus on core assets of China. Also, Shanjin Capital's investment is in the purpose of assisting investors to get a substantial share in the new round of China economic transformation.
Our investment fields focus on Key & Core Technology and Healthcare. In the aspect of Key & Core Technology, we deeply involved in 5G, AI and semiconductor also their subdivision tracks. We have invested in Cloudwalk, United Winner(688518.SH), Q&C silicon (605183.SH), SNC New Energy Technology, CorEnergy, Suzhou Huntersun, and Bailian.AI.
In the aspect of Healthcare, we focus on the fields of biotech, medical instruments, and molecular diagnostics. Our portfolio includes excellent enterprises such as Suzhou Zelgen Biopharmaceuticals (688266.SH), TINAVI (688277.SH), SHIP Biological, Genfleet Pharmaceutical, and Shanxi Micot, etc.
In the future, Shanjin team will adhere to the path of value investment, conduct in-depth research focus on Key & Core Technology companies with high technical barriers. We earnestly hope to grow with outstanding companies together and create long-term value for investors and society together.
